Merck Animal Health, known as MSD Animal Health outside the United States and Canada, announced the completion of its previously announced acquisition of the worldwide rights to Vecoxan (diclazuril), an oral suspension for the prevention of coccidiosis in calves and lambs, from Elanco Animal Health.
Elanco Animal Health Incorporated (NYSE: ELAN) announced today it signed an agreement with Merck Animal Health (also known as MSD Animal Health) to divest worldwide rights for Vecoxan® for $55 million in an all-cash deal. Vecoxan® is used for prevention and treatment of coccidiosis in calves and lambs